Deoxycholic acid as a modifier of the permeation of gliclazide through the blood brain barrier of a rat

Journal of Diabetes Research

Volumn 2013, Issue , 2013, Pages

  Lalić Popović, Mladena ^a   Vasović, Velibor ^a   Milijašević, Boris ^a   Goločorbin Kon, Svetlana ^a,b   Al Salami, Hani ^c   Mikov, Momir ^a,b  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b UNIVERSITY OF MONTENEGRO   (Montenegro)

^c CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCHOLIC ACID; GLICLAZIDE; GLUCOSE;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; BRAIN TISSUE; CONTROLLED STUDY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; MALE; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 84879378232     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2013/598603     Document Type: Article

References (39)

1. Ballabh P., Braun A., Nedergaard M., The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiology of Disease 2004 16 1 1 13 2-s2.0-2342471420 10.1016/j.nbd.2003.12.016 (Pubitemid 38569790)
2. Huber J. D., VanGilder R. L., Houser K. A., Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats. American Journal of Physiology 2006 291 6 H2660 H2668 2-s2.0-33845397903 10.1152/ajpheart.00489.2006 (Pubitemid 44904065)
3. McCall A. L., Millington W. R., Wurtman R. J., Metabolic fuel and amino acid transport into the brain in experimental diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America 1982 79 17 I 5406 5410 2-s2.0-0012728882 (Pubitemid 13233747)
4. Pocai A., Lam T. K. T., Obici S., Gutierrez-Juarez R., Muse E. D., Arduini A., Rossetti L., Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats. Journal of Clinical Investigation 2006 116 4 1081 1091 2-s2.0-33645531123 10.1172/JCI26640
5. Sandoval D. A., Obici S., Seeley R. J., Targeting the CNS to treat type 2 diabetes. Nature Reviews Drug Discovery 2009 8 5 386 398 2-s2.0-65449183851 10.1038/nrd2874
6. Rendell M., The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004 64 12 1339 1358 2-s2.0-3142728651 10.2165/00003495-200464120-00006 (Pubitemid 38916346)
7. O'Brien R. C., Luo M., Balazs N., Mercuri J., In vitro and in vivo antioxidant properties of gliclazide. Journal of Diabetes and Its Complications 2000 14 4 201 206 2-s2.0-0033811466 10.1016/S1056-8727(00)00084-2
8. Jennings P. E., Belch J. J. F., Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide. Metabolism 2000 49 2 23 26 2-s2.0-0033975557 (Pubitemid 30091789)
9. Fava D., Cassone-Faldetta M., Laurenti O., De Luca O., Ghiselli A., De Mattia G., Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in type 2 diabetes. Diabetic Medicine 2002 19 9 752 757 2-s2.0-0036047961 10.1046/j.1464-5491.2002.00762.x (Pubitemid 35013854)
10. Drouin P., Standl E., Sechser T., Thalassinos N., Halmos T., Nosadini R., Jonker J. J. C., Taton Y., Simoes Pereira C. M., Ametov A., Rovira A., Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2004 6 6 414 421 2-s2.0-6944221200 10.1111/j.1462-8902.2004.00404.x (Pubitemid 39409792)
11. Palmer K. J., Brogden R. N., Gliclazide: an update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 1993 46 1 92 125 2-s2.0-0027297136 (Pubitemid 23232408)
12. Ziegler O., Drouin P., Hemobiological properties of gliclazide. Journal of Diabetes and Its Complications 1994 8 4 235 239 2-s2.0-0028030191 10.1016/1056-8727(94)90050-7 (Pubitemid 24375631)
13. Benakis A., Glasson B., Keen H., Metabolic study of 14 C-labelled gliclazide in normal rats and in rats with streptozotocin-induced diabetes. Gliclazide and Treatment of Diabetes 1980 London, UK Academic Press and the Royal Society of Medicine 57 69
14. 3H]gliclazide in rats. European Journal of Drug Metabolism and Pharmacokinetics 1983 8 2 117 131 2-s2.0-0020531303 (Pubitemid 13073272)
15. Mikov M., Kevrešan S., Kuhajda K., Jakovljević V., Vasović V., 3 α7 α -dihydroxy-12-oxo-5 β -cholanate as blood-brain barrier permeator. Polish Journal of Pharmacology 2004 56 3 367 371 2-s2.0-3542993842 (Pubitemid 39010773)
16. Deli M. A., Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochimica et Biophysica Acta 2009 1788 4 892 910 2-s2.0-63249110007 10.1016/j.bbamem.2008.09.016
17. Greenwood J., Adu J., Davey A. J., Abbott N. J., Bradbury M. W. B., The effect of bile salts on the permeability and ultrastructure of the perfused, energy-depleted, rat blood-brain barrier. Journal of Cerebral Blood Flow and Metabolism 1991 11 4 644 654 2-s2.0-0025895384
18. Yang L., Zhang H., Fawcett J. P., Mikov M., Tucker I. G., Effect of bile salts on the transport of morphine-6-glucuronide in rat brain endothelial cells. Journal of Pharmaceutical Sciences 2011 100 4 1516 1524 2-s2.0-79951930856 10.1002/jps.22390
19. Heikkila R. E., The prevention of alloxan induced diabetes in mice by dimethyl sulfoxide. European Journal of Pharmacology 1977 44 2 191 193 2-s2.0-0017681502 10.1016/0014-2999(77)90106-6 (Pubitemid 8112866)
20. Szkudelski T., The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiological Research 2001 50 6 537 546 2-s2.0-0035691617 (Pubitemid 34087272)
21. Mikov M., Al-Salami H., Golocorbin-Kon S., Skrbic R., Raskovic A., Fawcett J. P., The influence of 3 α7 α -dihydroxy-12-keto-5 β -cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. European Journal of Drug Metabolism and Pharmacokinetics 2008 33 3 137 142 2-s2.0-56249104781
22. Tolia E., Fouyas I. P., Kelly P. A. T., Whittle I. R., The blood-brain barrier in diabetes mellitus: a critical review of clinical and experimental findings. International Congress Series 2005 1277 244 256 2-s2.0-33646462651 10.1016/j.ics.2005.02.027 (Pubitemid 43693333)
23. Al-Salami H., Kansara H., King J., Morar B., Jayathilaka B., Fawcett P. J., Bile acids: a bitter sweet remedy for diabetes. The New Zealand Pharmacy 2007 27 10 17 20
24. Al-Salami H., Butt G., Tucker I., Skrbic R., Golocorbin-Kon S., Mikov M., Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats. Archives of Drug Information 2008 1 1 35 41 2-s2.0-77953472691 10.1111/j.1753-5174.2008.00006.x
25. Al-Salami H., Butt G., Tucker I., Mikov M., Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacological Reports 2008 60 4 532 541 2-s2.0-52049107436
26. Al-Salami H., Butt G., Fawcett J. P., Tucker I. G., Golocorbin-Kon S., Mikov M., Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. European Journal of Drug Metabolism and Pharmacokinetics 2008 33 2 101 106 2-s2.0-51049103641
27. Al-Salami H., Butt G., Tucker I., Mikov M., Probiotic treatment proceeded by a single dose of bile acid and gliclazide exert the most hypoglycemic effect in type 1 diabetic rats. Medical Hypotheses and Research 2008 4 2 93 101
28. Al-Salami H., Butt G., Tucker I., Mikov M., Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods and Findings in Experimental and Clinical Pharmacology 2008 30 2 107 113 2-s2.0-44349086349 10.1358/mf.2008.30.2.1159652 (Pubitemid 351738270)
29. Mikov M., Boni N. S., Al-Salami H., Kuhajda K., Kevresan S., Golocorbin-Kon S., Fawcett J. P., Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta- cholanate, in healthy and diabetic rats. European Journal of Drug Metabolism and Pharmacokinetics 2007 32 1 7 12 (Pubitemid 46649805)
30. Al-Salami H., Butt G., Tucker I., Fawcett J. P., Mikov M., Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. The European Journal of Drug Metabolism and Pharmacokinetics 2009 37 2 99 108
31. Al-Salami H., Butt G., Tucker I., Fawcett P. J., Golocorbin-Kon S., Mikov I., Mikov M., Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. European Journal of Drug Metabolism and Pharmacokinetics 2009 34 1 43 50 2-s2.0-65649140524
32. Vasović V., The influence of bile acids derivatives on drug transfer into central nervous system [Ph.D. thesis] 1998 Novi Sad
33. Chaisson R. B., Anatomy to the White Rat 1973 5th Iowa, Canada William C. Brown, Dubuque
34. Hebei R., Stamberg M. W., Anatomy of the Laboratory Rat 1976 Baltimore, Md, USA Williams & Wilkins Company
35. Remko M., Theoretical study of molecular structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some hypoglycemic agents. Journal of Molecular Structure 2009 897 1-3 73 82 2-s2.0-59749100985 10.1016/j.theochem.2008.11.021
36. Yang L., Zhang H., Mikov M., Tucker I. G., Physicochemical and biological characterization of monoketocholic acid, a novel permeability enhancer. Molecular Pharmaceutics 2009 6 2 448 456 2-s2.0-64649093413 10.1021/mp800143w
37. Juliano R. L., Daoud S., Krause H. J., Grant C. W. M., Membrane-to-membrane transfer of lipophilic drugs used against cancer or infectious disease. Annals of the New York Academy of Sciences 1987 507 89 103 2-s2.0-0023633556
38. Ebling W. F., Wada D. R., Stanski D. R., From piecewise to full physiologic pharmacokinetic modeling: applied to thiopental disposition in the rat. Journal of Pharmacokinetics and Biopharmaceutics 1994 22 4 259 292 2-s2.0-0028561860 10.1007/BF02353622
39. Watanabe A., Fujiwara M., Tominaga S., Nagashima H., Bile acid and ammonia-induced brain edema in rats. Hiroshima Journal of Medical Sciences 1987 36 2 257 259 2-s2.0-0023355416